Showing 4291-4300 of 6036 results for "".
- Ace Vision Group Names Rob Kissling, MD, as Chief Medical Officerhttps://modernod.com/news/ace-vision-group-names-rob-kissling-md-as-chief-medical-officer-1/2481938/Ace Vision Group announced that it has named Rob Kissling, MD, as Chief Medical Officer. Dr. Kissling has more than 20 years of experience integrating clinical development, medical strategy, and business planning to develop and commercialize devices and medicines for ophthalmology.
- Ora and BlindCAN Film Festival Unveil 'The Blind Canvas Project' Using AI to Visualize the Human Experience of Blindnesshttps://modernod.com/news/ora-and-blindcan-film-festival-unveil-the-blind-canvas-project-using-ai-to-visualize-the-human-experience-of-blindness/2481937/Ora and BlindCAN Film Festival announced the launch of 'The Blind Canvas Project,' which aims to use storytelling and generative artificial intelligence (AI) to foster a deeper understanding of the lives and experiences of people living with inherited retinal disease, childhood visua
- Alcon Showcases Cloud-Based Planning and Digital Technologies During AAO 2023https://modernod.com/news/alcon-showcases-cloud-based-planning-and-digital-technologies-during-aao-2023/2481930/At the upcoming American Academy of Ophthalmology (AAO) 2023 annual meeting in San Francisco, Alcon will provide connected equipment ecosystems via its digital innovation technology. Ophthalmologists, surgical staff, researchers, and industry leaders will have the opportunity to ex
- Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment for its First Pivotal Clinical Trial of OTX-TKI in Wet AMDhttps://modernod.com/news/ocular-therapeutix-receives-fda-agreement-under-special-protocol-assessment-spa-for-its-first-pivotal-clinical-trial-of-otx-tki-in-wet-amd/2481928/Ocular Therapeutix announced it has received written agreement regarding the overall design from the FDA under a Special Protocol Assessment (SPA) for the company’s ongoing pivotal phase 3 clinical trial for Axpaxli (axitinib intravitreal implant), for the treatment of wet ag
- ViaLase Completes Enrollment for the VIA-002 Trial of the ViaLase Laser to Treat Primary Open Angle Glaucomahttps://modernod.com/news/vialase-completes-enrollment-for-the-via-002-trial-of-the-vialase-laser-to-treat-primary-open-angle-glaucoma/2481921/ViaLase announced it has completed enrollment of VIA-002, the company's pivotal trial of the ViaLase Laser to treat adult patients with primary open angle glaucoma (POAG). The ViaLase Laser combines the precision of femtosecond laser technology and the accuracy of micron-level image
- FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)https://modernod.com/news/fda-approves-genentechs-vabysmo-for-the-treatment-of-retinal-vein-occlusion-rvo/2481917/The FDA has approved Genentech's Vabysmo (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO). The approval for RVO marks the third indication for Vabysmo, along with wet age-related macular degeneration (AMD) and diabetic macular edem
- Vision Innovation Partners Names Chris Moore as CEOhttps://modernod.com/news/vision-innovation-partners-names-chris-moore-as-ceo/2481914/Vision Innovation Partners (VIP), a Mid-Atlantic eye care platform with nearly 70 locations, announced the promotion of existing board member and current President, Chris Moore, to Chief Executive Officer. Former CEO and founder Mike Dunn is now serving as Executive Vice President of Business Dev
- Bausch + Lomb Introduces New Surgical Planning Software for Eyetelligence Platformhttps://modernod.com/news/bausch-lomb-introduces-new-surgical-planning-software-for-eyetelligence-platform/2481907/Bausch + Lomb introduced new surgical planning software for the Eyetelligence platform designed to streamline surgical planning, information flow, and enable elect
- Lighthouse Guild Presents 2023 Awardshttps://modernod.com/news/lighthouse-guild-presents-2023-awards/2481905/Lighthouse Guild hosted its 2023 lecture and awards ceremony at its headquarters in New York on October 19. The awards recognize outstanding accomplishments in vision science, technological innovation, and advocacy. Wiley A. Chambers, MD, was awarded
- Stuart Therapeutics Enters License Agreement with Glaukos for Preclinical Glaucoma Drug Candidatehttps://modernod.com/news/stuart-therapeutics-enters-license-agreement-with-glaukos-for-preclinical-glaucoma-drug-candidate/2481904/Stuart Therapeutics has entered into a license agreement with Glaukos under which it has granted Glaukos exclusive worldwide rights to develop and commercialize Stuart's proprietary ST-113 drug candidate for neuroprotection in glaucoma. ST-113 is a pat